The trial met its primary endpoint, with patients receiving povetacicept achieving a 52.0% reduction in UPCR at Week 36
This new treatment option can redefine how we approach RRMM treatment by giving healthcare providers a regimen with improvement in PFS and OS and a well-characterized safety profile
The approval is backed by data showing deep, durable responses and manageable tolerability
It performs white blood cell differential counts and quantifies red blood cell and platelet morphology,
The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy
India plays a critical role in Bristol Myers Squibb’s global strategy
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas
Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
HYMPAVZI’s safety profile was generally favorable
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
